| |
De-risk your biological product supply with a seamless technology transfer. With more than 50 new product introductions in the last 12 months across biological modalities, Lonza is an experienced partner for clinical and commercial biological product manufacturing in liquid/lyo vials and prefilled syringes. Discover how.
|
|
Today’s Big NewsMay 13, 2024 |
| By Kevin Dunleavy Sanofi has earmarked more than 1 billion euros ($1.1 billion) to increase its manufacturing capacity at three sites in France, while Pfizer ($540 million) and AstraZeneca ($394 million) halve also revealed significant investments in the country as part of its "Choose France" summit. |
|
|
|
By James Waldron Takeda may be paring back its R&D pipeline in the name of efficiency, but the Japanese pharma has still found $100 million to ensure its clinical pipeline once again features an Alzheimer’s disease drug. |
By Conor Hale The agency has scheduled an advisory panel meeting May 23 to help evaluate the company’s Shield test, which is seeking an in vitro diagnostic approval for screening people ages 45 and up. |
By Nick Paul Taylor Boehringer Ingelheim has enlisted support for its attempt to prise AbbVie’s fingers off the Humira money faucet, signing an agreement to provide Cigna’s private label distributor with biosimilar copies of the aging blockbuster. |
|
Wednesday, May 22, 2024 | 10am ET / 7am PT In this webinar, we'll explore how emerging technologies aid Medical Affairs teams in understanding their research's online influence and reaching the right audiences. Topics include analyzing audience engagement, identifying influential opinion leaders, monitoring real-world conversations, and discovering emerging researchers. Register now.
|
|
By Angus Liu Facing potential sanctions from the Department of Defense and a recent allegation that it had transferred a U.S. client's data to Beijing without consent, WuXi AppTec is again rebutting claims of its ties with Chinese authorities. |
By James Waldron Merck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high rate of discontinuations rendered the trial's success unlikely. |
By Angus Liu Following AstraZeneca's setback in attempting to improve upon Imfinzi's efficacy in unresectable stage 3 lung cancer, a Bristol Myers Squibb endeavor has gone up in flames, as well. Now, market watchers are turning their attention to upcoming readouts from Merck & Co. and Roche. |
By Conor Hale The PulseSelect system aims to treat the world’s most common irregular heart rhythm, atrial fibrillation. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Nick Paul Taylor Sanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side of the deal, handing Sanofi ex-U.S. rights to a rare disease candidate that is leading Roche in a race to market. |
By Fraiser Kansteiner While much of the fanfare around COVID-19 treatments has dissipated, Shionogi has continued to press on in hopes that its Japan-approved protease inhibitor ensitrelvir could compete on a global stage. But a clinical misfire unveiled Monday has likely put a damper on those plans, at least in the U.S. |
By Andrea Park Social media is full of so-called wellness “hacks” that range from the weird but harmless to the downright damaging—and now, Bayer is taking to its own online feeds to battle that misinformation. |
Fierce podcastsDon’t miss an episode |
| This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
|
Wednesday, June 5, 2024 | 2pm ET / 11am PT Delayed diagnosis of autoimmune diseases is common due to subjective symptoms, lack of definitive testing, and gender bias. This can cause worsening symptoms and disease progression, while simultaneously leading to missed research opportunities and reduced revenue for pharma. Join us to learn about key advancements in RWD for helping address these issues. Register now.
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
